Skip to main content
HCPCS J1171 · Level II · Part B drug

J1171: hydromorphone (Dilaudid), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J1171

Billing unit
0.1 MG
Inj, hydromorphone, 0.1 mg
ASP payment limit
$0.224
October 2026; +64.7% vs July 2026
Practitioner MUE
240
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J1171 is the Level II code for Injection, hydromorphone, 0.1 mg, billed per 0.1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.224 per billing unit, up 64.7% from July 2026. The practitioner MUE allows up to 240 units per date of service (MAI 3), so a full 240-unit day is $53.76 at the current limit. Under OPPS it carries status indicator N. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 29 NDCs to it, sold as Hydromorphone HCl, Dilaudid by Pfizer Inc, Hikma Pharmaceuticals USA Inc., Teva Parenteral Medicines, Inc. No current Billing and Coding Article lists J1171, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1171 at $0.224 per 0.1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.136 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J1171
QuarterPayment limitPerCoinsurance
October 2026$0.2240.1 MG20%
July 2026$0.1360.1 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 29 NDCs from 4 labelers to J1171. Report the NDC in the claim's drug segment and bill the number of J1171 units that equals the quantity administered divided by 0.1 MG; the last column gives units per full package.

NDCs that crosswalk to J1171
NDCDrug nameLabelerPackage sizeBilling units / package
00409-1283-31Hydromorphone HClPfizer Inc1 × 10100
00409-1283-37Hydromorphone HClPfizer Inc1 × 10100
00409-1304-31Hydromorphone HClPfizer Inc1 × 10400
00409-1312-30Hydromorphone HClPfizer Inc1 × 10200
00409-1312-36Hydromorphone HClPfizer Inc1 × 10200
00409-1805-01Hydromorphone HClPfizer Inc0.5 × 1025
00409-2634-01Hydromorphone HClPfizer Inc1 × 101000
00409-2634-05Hydromorphone HClPfizer Inc5 × 105000
00409-2634-50Hydromorphone HClPfizer Inc50 × 15000
00409-3365-10Hydromorphone HClPfizer Inc1 × 10200
00409-4264-01Hydromorphone HClPfizer Inc0.5 × 1050
00641-2341-41Hydromorphone HClHikma Pharmaceuticals USA Inc.20 × 1400
00641-6151-25Hydromorphone HClHikma Pharmaceuticals USA Inc.1 × 25500
00641-6169-10Hydromorphone HClHikma Pharmaceuticals USA Inc.1 × 10100
00641-6206-10Hydromorphone HClHikma Pharmaceuticals USA Inc.0.5 × 1050
00641-6259-10Hydromorphone HClHikma Pharmaceuticals USA Inc.1 × 1020
00703-0018-01Hydromorphone HClTeva Parenteral Medicines, Inc.50 × 15000
00703-0110-03Hydromorphone HClTeva Parenteral Medicines, Inc.1 × 101000
00703-0113-03Hydromorphone HClTeva Parenteral Medicines, Inc.5 × 105000
63323-0851-10Hydromorphone HClFreseniUS Kabi USA, LLC1 × 101000
63323-0851-15Hydromorphone HClFreseniUS Kabi USA, LLC5 × 105000
63323-0851-50Hydromorphone HClFreseniUS Kabi USA, LLC50 × 15000
63323-0852-25Hydromorphone HClFreseniUS Kabi USA, LLC1 × 25250
63323-0853-25Hydromorphone HClFreseniUS Kabi USA, LLC1 × 25500
63323-0854-10Hydromorphone HClFreseniUS Kabi USA, LLC1 × 251000
76045-0009-06DilaudidFreseniUS Kabi USA, LLC0.5 × 1050
76045-0009-11DilaudidFreseniUS Kabi USA, LLC1 × 10100
76045-0010-11DilaudidFreseniUS Kabi USA, LLC1 × 10200
76045-0121-11Hydromorphone HClFreseniUS Kabi USA, LLC1 × 1020

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J1171. For practitioners the limit is 240 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J1171 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services2403 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital2403 Date of Service Edit: ClinicalPrescribing Information
DME supplier2403 Date of Service Edit: ClinicalPrescribing Information

MUE for J1171 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1171 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J1171 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J1171 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J1171 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Local coverage policies that list J1171

1 active Local Coverage Determination lists J1171 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J1171 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J1171 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J1171 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J1171

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J1171

What does HCPCS code J1171 describe?

J1171 is defined by CMS as "Injection, hydromorphone, 0.1 mg". Each billing unit represents 0.1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J1171 a CPT code?

No. J1171 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as hydromorphone (Dilaudid); CPT codes are five-character codes maintained by the AMA. On a Part B claim J1171 reports the drug itself in 0.1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J1171 in October 2026?

The ASP-based payment limit is $0.224 per 0.1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.136. Commercial payers use their own fee schedules.

How many units of J1171 can be billed per day?

The practitioner Medically Unlikely Edit is 240 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J1171?

The October 2026 ASP crosswalk lists 29 NDCs from 4 labelers: Hydromorphone HCl (Pfizer Inc); Hydromorphone HCl (Hikma Pharmaceuticals USA Inc.); Hydromorphone HCl (Teva Parenteral Medicines, Inc.); Hydromorphone HCl (FreseniUS Kabi USA, LLC). For example NDC 00409-1283-31 (package size 1) equals 100 billing units of J1171.

Does J1171 have NCCI bundling edits?

No active practitioner PTP pairs list J1171 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.